Board of Directors

Emil Billbäck has more than 25 years of experience in the life science industry, of which 11 years in senior leadership positions under private equity ownership. Emil is currently the CEO of Bonesupport AB, a leading company in orthobiology, bone healing and infection treatment.









Independent of The company and its executives.
Independent of major shareholders.
Holdings in Intervacc 0 shares
Member since 2024

Chairman of the board, former chairman at SOBI, QIAGEN och Lundbeck. Doctor of Medicine and docent at Karolinska Institutet with long-term experience of leading positions within the Life Science industry as CEO at Nycomed, as well as research manager at Pharmacia and Head of Ophtalmics of Astra Dracon, as well as the commercial division as Head of Northern Europe at Astra. Various other board assignments within both public and private companies, among others, at ATOS and Bonesupport.

Independent of The company and its executives.
Independent of major shareholders.
Holdings in Intervacc 1 847 147 shares
Member since 2023

Entrepreneur in equestrian sports, co-founder of Swedish Showjumping Horse Sales and the Swedish Equestrian Gala. Olympic rider in jumping and one of Sweden's biggest equestrian profiles and together with her husband Peder Fredricson (Olympic rider), she runs Grevlundagården, co-owner of Scandinavian Horse Event Production AB, Jönköping Horse Show and the online store Get the Gallop.





Independent of The company and its executives.
Independent of major shareholders.
Holdings in Intervacc 150 000 shares
Member since 2023

Professor emeritus in Bacteriology at Karolinska Institutet. Co-founder of Intervacc and has participated in the Company’s build-up, as Company’s Head of Research from 2000 to 2020 and its CEO from 2012 to 2018. Introduced Intervacc at First North in 2017. Has researched mechanisms to infections caused by staphylococci and streptococci and how bacteria adhere to tissue surfaces and how surface-localized proteins on the bacteria can be used as vaccine components. Has written more than 100 scientific articles on the subject.

Independent of The company and its executives.
Independent of major shareholders.
Holdings in Intervacc 317 970 shares
Member since 2023 (and 2000-2017)

MBA from Stockholm School of Economics with extensive experience from leading positions within Atlas Copco and Investor (2006-2015). Previous board assignments; Gambro, Mölnlycke, Lindorff, SAAB, Hi3G, SOBI, as well as a number of unlisted Life Sciences companies. Current board assignments: Bonesupport (of), Chalmers Ventures, Goco Development. Senior Advisor to Patricia Industries.





Independent of The company and its executives.
Independent of major shareholders.
Holdings in Intervacc 92 616 shares
Member since 2023

Marketing strategist and business developer. Former CEO and Creative Director at Ramfelt McCarthy advertising agency. Founder and editor in chief of Equipage equestrian magazine. Runs an equestrian facility.









Independent of The company and its executives.
Independent of major shareholders.
Holdings in Intervacc 40 000 shares
Member since 2023

Mathias Uhlen research protein science and precision medicine, has a PhD in biotechnology and works as a professor at both Karolinska Institutet and the Royal Institute of Technology in Stockholm. Mathias has previously held board assignments for the National committee for Biochemistry, HUPO international Antibody Initiative (HAI) and European Federation Biotechnology (EFB) and has an ongoing board assignment in the Swedish Research Council. Furthermore, Mathias is the editor for several journals, such as Protein Engineering, Design and Selection (PEDS) and Cell Systems.


Independent of The company and its executives.
Independent of major shareholders.
Holdings in Intervacc 181 669 shares
Member since 2024